All In Biotech

Drug Trial Radar · NCT03333109

Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)

Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

900

Actual

Start

Feb 8, 2018

Primary completion

Jan 13, 2020

Study completion Jan 13, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine

Conditions

  • Episodic Migraine

Interventions

  • ErenumabBiological

    70 mg/mL pre-filled syringe administered subcutaneously

  • PlaceboOther

    Matching placebo in pre-filled syringe administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Monthly Migraine Days at the Last Month (Month 3) of the Double-blind Treatment Period (DBTP)Time frame: Baseline up to Month 3

Locations

81 sites in 11 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Belagavi, India

  • Novartis Investigative Site

    Mumbai, India

  • Novartis Investigative Site

    New Delhi, India

  • Novartis Investigative Site

    Guntur, Andhra Pradesh, India

  • Novartis Investigative Site

    Ahmedabad, Gujarat, India

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    Mysore, Karnataka, India

  • Novartis Investigative Site

    Kochi, Kerala, India

  • Novartis Investigative Site

    Kochi, Kerala, India

  • Novartis Investigative Site

    Kozhikode, Kerala, India

  • Novartis Investigative Site

    Thiruvananthapuram, Kerala, India

  • Novartis Investigative Site

    Mumbai, Maharashtra, India

  • Novartis Investigative Site

    Mumbai, Maharashtra, India

  • Novartis Investigative Site

    Nagpur, Maharashtra, India

  • Novartis Investigative Site

    Nashik, Maharashtra, India

  • Novartis Investigative Site

    Nashik, Maharashtra, India

  • Novartis Investigative Site

    Pune, Maharashtra, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site

    Ludhiana, Punjab, India

  • Novartis Investigative Site

    Chennai, Tamil Nadu, India

  • Novartis Investigative Site

    Hyderabad, Telangana, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, India

  • Novartis Investigative Site

    Dehradun, Uttarakhand, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

  • Novartis Investigative Site

    Beirut, Lebanon

  • Novartis Investigative Site

    Beirut, Lebanon

  • Novartis Investigative Site

    Beirut, Lebanon

  • Novartis Investigative Site

    Beirut, Lebanon

  • Novartis Investigative Site

    El Chouf, LBN, Lebanon

  • Novartis Investigative Site

    Kuala Lumpur, Malaysia

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.